Esperion Therapeutics | ESPR - Pre Utilidad Fiscal





Pre Utilidad Fiscal Cambio Fecha
AbbVie USD 4.38B 1.92B 2025-09
Alnylam Pharmaceuticals USD 161.14M 77.83M 2025-12
Alterity Therapeutics Limited AUD -4.74M 3.53M 2024-12
Amarin USD -852K 7.26M 2025-12
Amgen USD 3.92B 2.35B 2025-09
Biogen USD 557.3M 186.7M 2025-09
BioMarin Pharmaceutical USD -26.32M 324.19M 2025-09
Cipla INR 11.69B 6.85B 2025-12
CSL USD 2.61B 1.21B 2025-12
Cytokinetics USD -183.03M 123.15M 2025-12
Daiichi Sankyo JPY 106.73B 48.96B 2025-12
Eli Lilly USD 7.23B 456M 2025-09
Esperion Therapeutics USD 63.67M 95M 2025-12
Geron USD -31.14M 12.72M 2025-12
Grifols EUR 257.85M 190.87M 2024-12
Halozyme Therapeutics USD 218.96M 14.02M 2025-09
Heron Therapeutics USD -2.95M 14.54M 2025-12
Ionis Pharmaceuticals USD -228M 99M 2025-12
Merck USD 6.74B 22M 2025-09
Minerva Neurosciences USD 22.51M 30.74M 2024-09
Moderna USD -187M 631M 2025-09
Nektar Therapeutics USD -37.05M 15.27M 2024-09
Pfizer USD 3.33B 290M 2025-09
PTC Therapeutics USD -139.08M 116.01M 2025-12
Puma Biotechnology USD 20.61M 24.76M 2024-09
Regeneron Pharmaceuticals USD 1.76B 244.6M 2025-09
Sanofi EUR -1.16B 5.5B 2025-12
Sarepta Therapeutics USD -407.67M 213.63M 2025-12
United Therapeutics USD 444M 6M 2025-12
Vanda Pharmaceuticals USD -22.92M 16.68M 2024-12